Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7081 to 7095 of 8314 results

  1. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

  2. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date:  13 January 2027

  3. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development Reference number: GID-TA11166 Expected publication date: TBC

  4. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

  5. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

  6. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

  7. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

  8. Hernia

    Discontinued Reference number: GID-CGWAVE0771

  9. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

  10. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

  11. Sepsis (QS161)

    November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.

  12. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1110.

  13. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

  14. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

  15. IQoro for hiatus hernia (MIB176)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.